Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

862
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
862
Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

5.2K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
5.2K
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

333
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
333
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

426
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
426

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deployment of COVID-19 Vaccines for Refugees and Migrants in Nepal.

Kathmandu University medical journal (KUMJ)·2026
Same author

The impact of co-occurring tumor suppressor mutations with mEGFR as early indicators of relapse in lung cancer.

ESMO open·2025
Same author

Patient Selection and Outcomes in Reirradiation for Head and Neck Cancers: A Prospective Cohort Study.

Clinical oncology (Royal College of Radiologists (Great Britain))·2025
Same author

Invisible Struggles: Exploring Challenges Faced by Women With Amputation in India.

Canadian prosthetics & orthotics journal·2024
Same author

Knowledge, Attitude and Practice in Recurrent Shoulder Dislocation: an analysis of patients presenting at a tertiary referral centre.

Kathmandu University medical journal (KUMJ)·2024
Same author

THE GUT-BRAIN AXIS: IMPLICATIONS FOR NEUROLOGICAL DISORDERS, MENTAL HEALTH, AND IMMUNE FUNCTION.

Georgian medical news·2023
Same journal

Best Practices in Physiologically Based Pharmacokinetic (PBPK) Modeling.

CPT: pharmacometrics & systems pharmacology·2026
Same journal

Integrated Population Pharmacokinetic Analysis of Intravitreal Aflibercept Drug Products.

CPT: pharmacometrics & systems pharmacology·2026
Same journal

Development and Use of a Population Pharmacokinetic Model for Characterizing the Pharmacokinetics of Vonoprazan in Pediatric Patients.

CPT: pharmacometrics & systems pharmacology·2026
Same journal

A Narrative Review of Artificial Intelligence for Drug Repurposing: Lessons From COVID-19 and Oncology (2020-2025).

CPT: pharmacometrics & systems pharmacology·2026
Same journal

Butorphanol Pharmacokinetics Across Species: Meta-Analysis Integrating Allometric Scaling and Minimal Physiologically Based Pharmacokinetic Modeling.

CPT: pharmacometrics & systems pharmacology·2026
Same journal

Accelerating Subcutaneous Drug Development: A Mechanistic Absorption Model for the Open Systems Pharmacology Framework.

CPT: pharmacometrics & systems pharmacology·2026
See all related articles

Related Experiment Video

Updated: Apr 29, 2026

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice
08:41

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice

Published on: October 27, 2014

22.6K

Model-based meta-analysis for quantifying Paclitaxel dose response in cancer patients.

D Lu1, A Joshi1, H Li2

  • 1Department of Clinical Pharmacology, Genentech, South San Francisco, California, USA.

CPT: Pharmacometrics & Systems Pharmacology
|May 23, 2014
PubMed
Summary
This summary is machine-generated.

Model-based meta-analysis reveals paclitaxel efficacy correlates with weekly dose, while safety depends on dose per administration. A weekly regimen of 65-80 mg/m(2) offers better efficacy and safety than a 3-week regimen of 175 mg/m(2).

More Related Videos

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids
06:25

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids

Published on: June 14, 2021

6.0K
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

14.0K

Related Experiment Videos

Last Updated: Apr 29, 2026

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice
08:41

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice

Published on: October 27, 2014

22.6K
High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids
06:25

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids

Published on: June 14, 2021

6.0K
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

14.0K

Area of Science:

  • Pharmacokinetics and Pharmacodynamics
  • Medical Oncology
  • Biostatistics

Background:

  • Paclitaxel is a vital chemotherapy agent used in various cancers.
  • Optimal dosing and administration schedules are crucial for maximizing efficacy and minimizing toxicity.
  • Previous studies have suggested varying outcomes based on paclitaxel dose and regimen.

Purpose of the Study:

  • To quantify the effects of paclitaxel dose and administration schedule (weekly vs. every 3 weeks) on treatment efficacy and safety.
  • To guide optimal dose and regimen selection for paclitaxel therapy in cancer patients.
  • To establish dose-response relationships for paclitaxel efficacy and safety outcomes.

Main Methods:

  • A model-based meta-analysis was conducted on data from 29 paclitaxel monotherapy trials.
  • Logistic regression models were used to assess the relationship between dose and objective response or neutropenia rates.
  • Survival models were employed to evaluate the impact of dose on overall survival and progression-free survival.

Main Results:

  • Paclitaxel efficacy, including objective response rate and survival metrics, was correlated with the average weekly dose (mg/m(2)/week).
  • Paclitaxel safety, specifically neutropenia incidence, was correlated with the dose administered per administration (mg/m(2)).
  • A weekly regimen of 65-80 mg/m(2) demonstrated comparable or superior efficacy with a lower incidence of neutropenia compared to an every-3-week regimen of 175 mg/m(2).

Conclusions:

  • The findings support a weekly paclitaxel regimen at 65-80 mg/m(2) as a potentially more effective and safer option than the standard every-3-week regimen.
  • Dose per week and dose per administration are critical determinants of paclitaxel's efficacy and safety profile, respectively.
  • Model-based meta-analysis provides a robust framework for optimizing chemotherapy dosing strategies.